LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome‐negative B‐precursor acute lymphoblastic leukaemia in first relapse

Photo from wikipedia

Adults with relapsed or refractory B‐precursor acute lymphoblastic leukaemia (R/R BCP‐ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP‐ALL. We aimed to assess the… Click to show full abstract

Adults with relapsed or refractory B‐precursor acute lymphoblastic leukaemia (R/R BCP‐ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP‐ALL. We aimed to assess the activity of blinatumomab in concomitant association with intensive chemotherapy. Seventeen patients with R/R BCP‐ALL were treated with combination of blinatumomab and VANDA (etoposide, cytarabine, mitoxantrone, dexamethasone and asparaginase) regimen. Complete remission (CR) was achieved in 14/17 patient (82%) and 11/17 (65%) were transplanted. One‐year leukaemia‐free survival was 58.8% for the whole cohort and 90.9% for transplanted patients. These preliminary data suggest that the VANDA‐blinatumomab salvage regimen leads to a very high rate of CR and HSCT in suitable patients.

Keywords: leukaemia; lymphoblastic leukaemia; precursor acute; acute lymphoblastic; blinatumomab

Journal Title: British Journal of Haematology
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.